Results 241 to 250 of about 75,067 (341)

Release of Bioactive Peptides from Whey Protein During In Vitro Digestion and Their Effect on CCK Secretion in Enteroendocrine Cells: An In Silico and In Vitro Approach. [PDF]

open access: yesMolecules
Ignot-Gutiérrez A   +6 more
europepmc   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj   +6 more
wiley   +1 more source

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Objective This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss. Methods We included 98 patients with obesity treated with liraglutide 3.0 mg.
Susanne Kuckuck   +7 more
wiley   +1 more source

Precision nutrition in weight loss and neuroendocrine control of people with obesity: The study protocol of a factorial randomised controlled trial (GenON Programme)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Precision nutrition, guided by genetic testing, has emerged as a promising approach for managing obesity. However, robust clinical trials testing its effectiveness in real‐world dietary interventions remain scarce. The GenOn Programme aims to evaluate whether tailoring nutritional care based on genetic risk for obesity enhances weight ...
Karla P. Balbino   +11 more
wiley   +1 more source

Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Shobha Bhattachar   +8 more
wiley   +1 more source

Parental Culinary Skills and Children's Eating Behavior in Brazil: A Cross-Sectional Study. [PDF]

open access: yesNutrients
Dos Santos TS   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy